95360-33-1

Basic information

• Product Name: 4-(Chloromethyl)-phenylacetic acid methyl ester
• Synonyms: 4-(Chloromethyl)-phenylacetic acid methyl ester;2-(ChloroMethyl)-benzeneacetic acid Methyl ester;Methyl 2-[2-(Chloromethyl)Phenyl]Acetate;Methyl 2-[2-(Chloromethyl)Phenyl]Acetate(WX630300)
• CAS NO: 95360-33-1
• Molecular Formula: C₁₀H₁₁ClO₂
• Molecular Weight: 198.65
• Mol File: 95360-33-1.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 272.2±20.0 °C(Predicted)
• Appearance: /
• Density: 1.168±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 4-(Chloromethyl)-phenylacetic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Chloromethyl)-phenylacetic acid methyl ester(95360-33-1)
• EPA Substance Registry System: 4-(Chloromethyl)-phenylacetic acid methyl ester(95360-33-1)

Safety Data

• Hazardous Substances Data: 95360-33-1(Hazardous Substances Data)

Usage

Description

4-(Chloromethyl)-phenylacetic acid methyl ester is an organic compound that serves as a building block in the synthesis of various pharmaceuticals and bioactive molecules. It is characterized by the presence of a chloromethyl group attached to a phenylacetic acid framework, with a methyl ester group providing additional reactivity and functionality.

Uses

Used in Pharmaceutical Industry:
4-(Chloromethyl)-phenylacetic acid methyl ester is used as a key intermediate in the synthesis of flavonoids, which are a class of compounds with diverse biological activities. Specifically, it is utilized in the production of aromatase inhibitors, a type of drug that helps regulate hormone levels and is used in the treatment of conditions such as breast cancer.
Used in Chemical Synthesis:
As a building block compound, 4-(Chloromethyl)-phenylacetic acid methyl ester is also employed in the synthesis of other complex organic molecules and pharmaceutical agents. Its versatile structure allows for further functionalization and modification, making it a valuable component in the development of new drugs and bioactive compounds.

Upstream product

• 4385-35-7 isochroman-3-one 
• 67-56-1 methanol 
• 6772-67-4 2-chloromethylphenylacetyl chloride 
• 95335-46-9 2-chloromethylphenylacetic acid 

Downstream Products

• 278611-07-7 methyl 2-(2-chloromethylphenyl)-3-hydroxyacrylate 
• 117428-95-2 methyl 2-(2'-chloromethylphenyl)-3-methoxyacrylate 
• 187327-30-6 2-[6-(trifluoromethyl)-2-pyridyloxymethyl]phenylacetic acid methyl ester 

Relevant articles and documents

Method for preparing 2-(6-trifluoromethylpyridine-2-yloxymethyl) methyl phenylacetate

The invention provides a method for preparing methyl 2-(6-trifluoromethylpyridine-2-yloxymethyl) phenylacetate, and belongs to the technical field of preparation of pesticide intermediates. The preparation method comprises the following steps: by taking 3

Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects in Vivo

Signal peptide peptidase-like 2a (SPPL2a) is an aspartic intramembrane protease which has recently been shown to play an important role in the development and function of antigen presenting cells such as B lymphocytes and dendritic cells. In this paper, we describe the discovery of the first selective and orally active SPPL2a inhibitor (S)-2-cyclopropyl-N1-((S)-5,11-dioxo-10,11-dihydro-1H,3H,5H-spiro[benzo[d]pyrazolo[1,2-a][1,2]diazepine-2,1′-cyclopropan]-10-yl)-N4-(5-fluoro-2-methylpyridin-3-yl)succinamide 40 (SPL-707). This compound shows adequate selectivity against the closely related enzymes γ-secretase and SPP and a good pharmacokinetic profile in mouse and rat. Compound 40 significantly inhibited processing of the SPPL2a substrate CD74/p8 fragment in rodents at doses ≤10 mg/kg b.i.d. po. Oral dosing of 40 for 11 days at ≥10 mg/kg b.i.d. recapitulated the phenotype seen in Sppl2a knockout (ko) and ENU mutant mice (reduced number of specific B cells and myeloid dendritic cells). Thus, we believe that SPPL2a represents an interesting and druggable pharmacological target, potentially providing a novel approach for the treatment of autoimmune diseases by targeting B cells and dendritic cells.

NOVEL CRYSTALLINE FORM OF PICOXYSTROBIN, METHOD OF PREPARING AND USE OF THE SAME

A novel crystalline form of the compound of formula (I) (picoxystrobin) is provided. The novel crystalline form of picoxystrobin may be prepared by crystallization from solution in a suitable solvent. Fungicidal compositions comprising the novel crystalline form, a method for controlling fungal infestations at a locus and a use of the novel crystalline form are also provided.